工商銀行(601398.SH)擬發行29億美元境外優先股
格隆匯9月17日丨工商銀行(601398.SH)公佈,該行於北京時間2020年9月16日深夜完成擬發行境外優先股的定價及分配。該行將發行29億美元、年股息率為3.58%的非累積永續境外優先股。
該行於2020年9月16日與聯席牽頭經辦人簽訂認購協議。境外優先股將根據相關法律法規、中國證券監督管理委員會等監管機構有關批覆的要求及該行股東大會的授權發行。
境外優先股發行所募集的資金在扣除承銷佣金及與發行有關的費用後將被用於補充該行其他一級資本,提高該行資本充足率。該行預期境外優先股的發行將於2020年9月23日完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.